IQ-AI Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IQAI.L research report →
Companywww.imagingbiometrics.com/iq-ai-ltd
IQ-AI Limited, through its subsidiaries, develops software applications for the healthcare industry in Jersey and the United States. Its products include IB Clinic, a toolkit of post-processing software plug-ins for integrating into existing medical image visualization applications; IB Rad Tech, a workflow engine that processes customized workflows; IB Neuro, which analyzes MR data sets and generates parametric perfusion maps quantifying changes in contrast over time; and IB Delta Suite that performs a various fundamental radiology operations, including image co-registration, subtraction, class map generation, and export. The company also offers IB DCE, which analyzes conventional T1 weighted images and generates an array of relevant perfusion and permeability parameters; IB Diffusion that analyzes MR diffusion-weighted images and generates apparent diffusion coefficient, extrapolated b-value, IVIM, and other parameter maps; and IB StoneChecker, a medical software tool to aid clinical decision making by providing information about a patient's kidney stone.
- CEO
- Trevor Edward Brown
- IPO
- 1993
- Employees
- 7
- HQ
- Saint Helier, JE
Price Chart
Valuation
- Market Cap
- $2.04M
- P/E
- -3.17
- P/S
- 1.56
- P/B
- 3.42
- EV/EBITDA
- -4.10
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 91.70%
- Op Margin
- -43.66%
- Net Margin
- -43.61%
- ROE
- -164.60%
- ROIC
- -108.26%
Growth & Income
- Revenue
- $750.11K · 23.09%
- Net Income
- $-327,103 · 47.56%
- EPS
- $-0.00 · 55.88%
- Op Income
- $-327,518
- FCF YoY
- 22.30%
Performance & Tape
- 52W High
- $2.10
- 52W Low
- $0.72
- 50D MA
- $0.84
- 200D MA
- $1.22
- Beta
- 2.60
- Avg Volume
- 674.96K
Get TickerSpark's AI analysis on IQAI.L
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our IQAI.L Coverage
We haven't published any research on IQAI.L yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IQAI.L Report →